A Review: Uses of Thalidomide in Cancer Treatment
Abstract
Thalidomide is an anti-angiogenetic agent, which was widely used in early 1950s and 1960s for the treatment of morning sickness in pregnant women. The drug has been banned in1960 as it caused severe birth defects in children whose mothers had used thalidomide during pregnancy. Though it caused severe adverse effects the drug has found to be effective in the treatment of leprosy and multiple myeloma. These days thalidomide has been successfully used in cancer patents and patients with leprosy.
Keywords: Thalidomide, Cancer, Types of cancer, Stem cell transplantation
Cite this Article
Anusha Sudulaguntla, Jobin Joy, Mary Rathna KM et al. A Review: Uses of Thalidomide in Cancer Treatment. Research & Reviews: A Journal of Pharmacology. 2018; 8(1): 1–5p.
Keywords
Full Text:
PDFReferences
Dr. Ananya mandal MD.History of Thalidomide. News Medical Life Sciences. 2005.
--------------------------------------------------------------------------
Neil Vargesson. Thalidomide induced teratogenesis; history and mechanisms. U S National Library of medicine National Institute of Health. 2015; 105(2); 140-156.
--------------------------------------------------------------------------
Waqas Rehman, Lisa M Arfons, Hillard M Lazarus. The rise fall and subsequent triumph of Thalidomide: lessons learned in drug development U S National Library of medicine National Institute of Health.2011; 2(5); 219-308.
--------------------------------------------------------------------------
Ridings JE, The Thalidomide Disaster, lesson from the past, U S National Library of medicine National Institute of Health.2013; 947 (10); 575- 586.
--------------------------------------------------------------------------
Goldman DA, Thalidomide use; past history and current implication in practice. U S National Library of medicine National Institute of Health.2001; 28(3); 471-7.
--------------------------------------------------------------------------
Steve K Teo, Wayne A. Colburn, Karin A. Kook, David I. Striling, Markian S. Jaworsky, Micheal A. Scheffler, Steve D. Thomas, Oscar L. Laskin, Clinical pharmacokinetics of Thalidomide, Clinical Pharmacokinetics.2004 ; 43 (5) ; 311-327
--------------------------------------------------------------------------
https://www.drugbank.ca/drugs/DB01041
--------------------------------------------------------------------------
Olson K, Hall T, Horton J, Khung C. Thalidomide (N-phthaloylglutamimide> in the treatment of advanced cancer. Clinical Pharmacology & Therapeutics. 1965; 6(3):292-297.
--------------------------------------------------------------------------
Grabstald H, Golbey R. Clinical experiences with thalidomide in patients with cancer. Clinical Pharmacology & Therapeutics. 1965; 6(3):298-302.
--------------------------------------------------------------------------
Singhal S, Mehta J, Desikan R, Ayers D, Roberson P, Eddlemon P et al. Antitumor Activity of Thalidomide in Refractory Multiple Myeloma. New England Journal of Medicine. 1999; 341(21):1565-1571.
--------------------------------------------------------------------------
http://Weber DM, Rankin K, Gavino M, et al: Thalidomide with dexamethasone for resistant multiple myeloma (abstract 719). Blood 96:167a, 2000.
--------------------------------------------------------------------------
http://Barlogie B, Desikan R, Munshi N, et al: Single course DT-PACE antiangiochemotherapy effects CR in plasma cell leukemia and fulminant multiple myeloma. Blood 92(suppl 1):273b, 1998
--------------------------------------------------------------------------
Weber D, Rankin K, Gavino M, Delasalle K, Alexanian R. Thalidomide Alone or With Dexamethasone for Previously Untreated Multiple Myeloma. Journal of Clinical Oncology. 2003; 21(1):16-19.
--------------------------------------------------------------------------
Dimopoulos M, Zomas A, Viniou N, Grigoraki V, Galani E, Matsouka C et al. Treatment of Waldenstrom’s Macroglobulinemia With Thalidomide. Journal of Clinical Oncology. 2001; 19(16):3596-3601.
--------------------------------------------------------------------------
Mesa R. A phase 2 trial of combination low-dose thalidomide and prednisone for the treatment of myelofibrosis with myeloid metaplasia. Blood. 2002; 101(7):2534-2541.
--------------------------------------------------------------------------
Thomas D, Estey E, Giles F, Faderl S, Cortes J, Keating M et al. Single agent thalidomide in patients with relapsed or refractory acute myeloid leukaemia. British Journal of Haematology. 2003; 123(3):436-441.
--------------------------------------------------------------------------
Attal M, Harousseau J, Leyvraz S, Doyen C, Hulin C, Benboubker L et al. Maintenance therapy with thalidomide improves survival in patients with multiple myeloma. Blood. 2006; 108(10):3289-3294.
--------------------------------------------------------------------------
Spencer A, Prince H, Roberts A, Prosser I, Bradstock K, Coyle L et al. Consolidation Therapy With Low-Dose Thalidomide and Prednisolone Prolongs the Survival of Multiple Myeloma Patients Undergoing a Single Autologous Stem-Cell Transplantation Procedure. Journal of Clinical Oncology. 2009; 27(11):1788-1793.
--------------------------------------------------------------------------
Raina V, Sharma A, Anand M, Kumar R, Khaitan B, Grover J et al. Use of simple hematological, biochemical and clinical parameters to monitor response of multiple myeloma patients on high dose thalidomide therapy. Indian Journal of Cancer. 2005; 42(1):46.
--------------------------------------------------------------------------
James H. Kim, Anthony R. Scialli, Thalidomide; The Tragedy of Birth Defects and the Effective Treatment of Disease, Toxicological Sciences, U S National Library of medicine National Institute of Health. 2011; 122(1); 1-6.
--------------------------------------------------------------------------
J. K Grover, G. Uppal, V Raina, The adverse effects of thalidomide in relapsed and rerfractory patients of multiple myeloma. Annals of Oncology. 2002; 13(10); 1636-1640.
--------------------------------------------------------------------------
Gramage Caro T, Orbe Izquierdo S, Perez Meneedez-conde C, Palomar Fernandez C, Munoz Garcia M, Bermejo Vicedo T. Adverse drug reactions in thalidomide treated patients, European Association of Hospital Pharmacists, 2008.
--------------------------------------------------------------------------
Virginia C. Hall, Rokea A. El-azhary, Saskia Bouwhuis, S. Vincent Rajkumar. Dermatologic side effect of Thalidomide in patient with Multiple Myeloma. Journal of the American academy of dermatology. 2002; 28:542-7.
--------------------------------------------------------------------------
Refbacks
- There are currently no refbacks.
Copyright (c) 2018 Research & Reviews: A Journal of Pharmacology